Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulpal revitalization versus Emdogain for necrotic immature teeth
RBR-336mnhRecruiting
- Sponsor
- Universidade Ceuma
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of enamel matrix derivative in pulpal necrosis (2 arms), sponsored by Universidade Ceuma. Primary endpoints: Clinical treatment outcome and Radiographic treatment outcome. Started Nov 2018; status: recruiting.
02
Drugs
enamel matrix derivative
03
Conditions
pulpal necrosis
Beyond the preview
Go deeper on RBR-336mnh.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-336mnh.